393 related articles for article (PubMed ID: 27986748)
21. Programmed Death Ligand 1 (PD-L1) Expression in Epithelial Ovarian Cancer: A Comparison of Type I and Type II Tumors.
Nhokaew W; Kleebkaow P; Chaisuriya N; Kietpeerakool C
Asian Pac J Cancer Prev; 2019 Apr; 20(4):1161-1169. PubMed ID: 31030490
[TBL] [Abstract][Full Text] [Related]
22. Prognostic and Clinical Value of Interleukin 6 and CD45
Wertel I; Suszczyk D; Pawłowska A; Bilska M; Chudzik A; Skiba W; Paduch R; Kotarski J
J Immunol Res; 2020; 2020():1715064. PubMed ID: 33062717
[TBL] [Abstract][Full Text] [Related]
23. Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer.
Kim HS; Kim JY; Lee YJ; Kim SH; Lee JY; Nam EJ; Kim S; Kim SW; Kim YT
Gynecol Oncol; 2018 Dec; 151(3):414-421. PubMed ID: 30314669
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of PD-1 and PD-L1 positive tumor-infiltrating immune cells in ovarian carcinoma.
Buderath P; Mairinger F; Mairinger E; Böhm K; Mach P; Schmid KW; Kimmig R; Kasimir-Bauer S; Bankfalvi A; Westerwick D; Hager T
Int J Gynecol Cancer; 2019 Nov; 29(9):1389-1395. PubMed ID: 31492714
[TBL] [Abstract][Full Text] [Related]
25. PD-1/PD-L1 expression and tumor-infiltrating lymphocytes are prognostically favorable in advanced high-grade serous ovarian carcinoma.
Martin de la Fuente L; Westbom-Fremer S; Arildsen NS; Hartman L; Malander S; Kannisto P; Måsbäck A; Hedenfalk I
Virchows Arch; 2020 Jul; 477(1):83-91. PubMed ID: 31980961
[TBL] [Abstract][Full Text] [Related]
26. Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies.
Mortensen JB; Monrad I; Enemark MB; Ludvigsen M; Kamper P; Bjerre M; d'Amore F
Eur J Haematol; 2021 Jul; 107(1):81-91. PubMed ID: 33721375
[TBL] [Abstract][Full Text] [Related]
27. Prognostic effect of programmed death-ligand 1 (PD-L1) in ovarian cancer: a systematic review, meta-analysis and bioinformatics study.
Wang L
J Ovarian Res; 2019 Apr; 12(1):37. PubMed ID: 31039792
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical analysis and prognostic significance of PD-L1, PD-1, and CD8+ tumor-infiltrating lymphocytes in Ewing's sarcoma family of tumors (ESFT).
Machado I; López-Guerrero JA; Scotlandi K; Picci P; Llombart-Bosch A
Virchows Arch; 2018 May; 472(5):815-824. PubMed ID: 29445891
[TBL] [Abstract][Full Text] [Related]
29. The increase of circulating PD-L1-expressing CD68(+) macrophage in ovarian cancer.
Qu QX; Huang Q; Shen Y; Zhu YB; Zhang XG
Tumour Biol; 2016 Apr; 37(4):5031-7. PubMed ID: 26541760
[TBL] [Abstract][Full Text] [Related]
30. [The content of the soluble forms PD-1 and PD-L1 in blood serum of patients with gastric cancer and their relationship with clinical and morphological characteristics of the disease.].
Gershtein ES; Ognerubov NA; Chang VL; Delektorskaya VV; Korotkova EA; Sokolov NY; Polikarpova SB; Stilidi IS; Kushlinskii NE
Klin Lab Diagn; 2020; 65(6):347-352. PubMed ID: 32459892
[TBL] [Abstract][Full Text] [Related]
31. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.
Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA
Clin Cancer Res; 2017 Sep; 23(17):5024-5033. PubMed ID: 28512174
[No Abstract] [Full Text] [Related]
32. Prognostic value of tumor PD-L1 expression combined with CD8
Wang Q; Lou W; Di W; Wu X
Int Immunopharmacol; 2017 Nov; 52():7-14. PubMed ID: 28846888
[TBL] [Abstract][Full Text] [Related]
33. High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer.
Okuma Y; Hosomi Y; Nakahara Y; Watanabe K; Sagawa Y; Homma S
Lung Cancer; 2017 Feb; 104():1-6. PubMed ID: 28212990
[TBL] [Abstract][Full Text] [Related]
34. Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study.
Hu LY; Xu XL; Rao HL; Chen J; Lai RC; Huang HQ; Jiang WQ; Lin TY; Xia ZJ; Cai QQ
Chin J Cancer; 2017 Dec; 36(1):94. PubMed ID: 29246182
[TBL] [Abstract][Full Text] [Related]
35. Peripheral cytokine levels as predictive biomarkers of benefit from immune checkpoint inhibitors in cancer therapy.
Ji S; Chen H; Yang K; Zhang G; Mao B; Hu Y; Zhang H; Xu J
Biomed Pharmacother; 2020 Sep; 129():110457. PubMed ID: 32887027
[TBL] [Abstract][Full Text] [Related]
36. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S
Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968
[TBL] [Abstract][Full Text] [Related]
37. Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between Tissue and Serum PD-L1 Expression.
Shigemori T; Toiyama Y; Okugawa Y; Yamamoto A; Yin C; Narumi A; Ichikawa T; Ide S; Shimura T; Fujikawa H; Yasuda H; Hiro J; Yoshiyama S; Ohi M; Araki T; Kusunoki M
Ann Surg Oncol; 2019 Mar; 26(3):876-883. PubMed ID: 30565045
[TBL] [Abstract][Full Text] [Related]
38. Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection.
Eto S; Yoshikawa K; Nishi M; Higashijima J; Tokunaga T; Nakao T; Kashihara H; Takasu C; Iwata T; Shimada M
Gastric Cancer; 2016 Apr; 19(2):466-471. PubMed ID: 26210691
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors.
Cierna Z; Mego M; Miskovska V; Machalekova K; Chovanec M; Svetlovska D; Hainova K; Rejlekova K; Macak D; Spanik S; Ondrus D; Kajo K; Mardiak J; Babal P
Ann Oncol; 2016 Feb; 27(2):300-5. PubMed ID: 26598537
[TBL] [Abstract][Full Text] [Related]
40. The immune suppressive factors CD155 and PD-L1 show contrasting expression patterns and immune correlates in ovarian and other cancers.
Smazynski J; Hamilton PT; Thornton S; Milne K; Wouters MCA; Webb JR; Nelson BH
Gynecol Oncol; 2020 Jul; 158(1):167-177. PubMed ID: 32446718
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
